SARS-CoV-2 replication-transcription complex (RTC) (RTC)

The SARS-CoV-2 replication-transcription complex (RTC) is a sophisticated multi-protein assembly responsible for the synthesis of viral genomic and subgenomic RNA [V'kovski et al., 2021, Nature Reviews Microbiology]. The core of this machinery is the RNA-dependent RNA polymerase (RdRp, nsp12), which works in conjunction with cofactors nsp7 and nsp8 to catalyze RNA polymerization [Hillen et al., 2020, Nature]. The machinery also includes the nsp13 helicase for unwinding RNA duplexes and the nsp14 exonuclease, which provides a rare proofreading capability that enhances replication fidelity [Yan et al., 2021, Science]. Additionally, the viral proteases nsp5 (Main Protease) and nsp3 (Papain-like Protease) are essential for processing the large viral polyproteins into functional units [NIH, 2024]. Because these components are vital for the viral life cycle and lack direct human homologs, they serve as primary targets for antiviral therapies like Remdesivir and Nirmatrelvir [PubMed, 2023]. Inhibition of these enzymes effectively halts viral replication and reduces the severity of COVID-19 [StatPearls, 2023]. The complex's structural conservation across variants makes it a robust target for therapeutic intervention [Nature, 2022].

Other names

SARS-CoV-2 replicase complexSARS-CoV-2 replication machinerySARS-CoV-2 multi-protein replication complexSARS-CoV-2 RTC

The machinery is targeted by nucleoside analogs that act as alternative substrates for the RdRp, leading to premature RNA chain termination or lethal mutagenesis, and by small-molecule inhibitors of the Main Protease (Mpro) that prevent the cleavage of viral polyproteins into functional units.